logo-loader

PureTech Health affiliate inks major deal with Japanese pharma

Published: 03:06 07 Mar 2019 EST

ADHD graphic
One of the drugs being developed is for attention deficit disorder

PureTech Health PLC (LON:PRTC) said its affiliate company has inked a major deal with a Japanese pharma worth US$20mln upfront and up to US$105mln in potential milestone payments.

The firm, Akili, is developing digital medicines AKL-T01 and AKL-T02.

The former is currently under review with the US Food and Drug Administration as a potential digital treatment for children with attention-deficit hyperactivity disorder, while the latter is in late-stage trials in children with an autism spectrum disorder.

The partnership with Shionogi & Co covers the markets of Japan and Korea.

BenevolentAI advances novel ulcerative colitis treatment through Phase 1a trial

BenevolentAI (OTC:BAIVF) chief scientific officer Dr Anne Phelan joins Proactive's Stephen Gunnion with positive safety data from the Phase 1a, first-in-human, clinical study of BEN-8744 in healthy volunteers. Phelan explained that BEN-8744 is a potent, selective PD10 inhibitor, uniquely...

2 hours, 25 minutes ago